Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CONy 2020 | The future of Alzheimer’s disease: aducanumab

John Hardy • 20 Oct 2020
CONy 2020
Alzheimer’s Disease Aducanumab Antibodies
EMERGE ENGAGE

John Hardy, PhD, University College London, London, UK, discusses the aducanumab clinical trial (NCT02477800, NCT024845470), which indicated that the antibody had marginal positive effects. If this is correct, it could have significant implications for Alzheimer’s disease, although it will need to be used in conjunction with other treatments. Additionally, the incidence of Alzheimer’s disease has dropped by 20% over the last 20 years. This is attributed to the increase in better cardiac health. This interview took place during the Virtual World Congress on Controversies in Neurology (CONy) 2020.

Disclosures

John Hardy occasionally consults for Eisai and is on the SAB of the biotech Ceracuity.

More from John Hardy

2:20
Cross neurodegenerative disease genetic analysis: similarities and differences
John Hardy • 20 Oct 2020
2:00
The benefits of GWAS in understanding Alzheimer’s disease
John Hardy • 20 Oct 2020

Related Videos

5:46
The impact of hypertension on neurovascular function in neurodegenerative diseases
Costantino Iadecola • 6 Feb 2024
3:26
Should endovascular thrombectomy be used in patients with pre-morbid dementia?
Aravind Ganesh • 20 Feb 2024
5:09
Defining the neurovasculome: advances in brain health research
Costantino Iadecola • 6 Feb 2024
3:55
The impact of the neurovasculome on cognitive function in neurodegenerative diseases
Costantino Iadecola • 6 Feb 2024
The content of VJNeurology is intended for healthcare professionals